Bionovo has presented positive results from an open-label, randomised trial evaluating Menerba (MF101) as a treatment for hot flashes associated with the menopause.

The primary goal of the study was to evaluate the safety and tolerability of two doses of Menerba, higher than those previously tested during Phase II studies, after four weeks of treatment.

The results showed that Menerba is a safe therapy.

The company has established a definitive dosing strategy for a Phase III clinical trial.

Bionovo president and chief medical officer Mary Tagliaferri said after four weeks of therapy, the reduction in moderate to severe hot flashes was approximately 70%.

“In addition, there was a 68% reduction in the number of night-time awakenings due to hot flashes,” Tagliaferri added.